Market Closed -
Other stock markets
|
After market 04:23:56 pm | |||
2.04 USD | -51.31% | 1.95 | -4.41% |
Financials (USD)
Sales 2024 * | 85.93M | Sales 2025 * | 72.15M | Capitalization | 284M |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | -49M | EV / Sales 2024 * | 3.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.93 x |
P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-9.23
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.82% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -42.96% | ||
1 week | -46.89% | ||
Current month | +46.63% | ||
1 month | +17.74% | ||
3 months | +57.24% | ||
6 months | +99.18% | ||
Current year | +54.20% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 2.04 | -51.31% | 40 451 938 |
24-05-08 | 4.19 | +2.95% | 40,523,342 |
24-05-07 | 4.07 | -6.86% | 4,440,551 |
24-05-06 | 4.37 | -1.35% | 5,076,011 |
24-05-03 | 4.43 | -1.56% | 11,087,858 |
Delayed Quote Nasdaq, May 09, 2024 at 12:48 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.20% | 284M | |
+2.69% | 108B | |
+10.07% | 105B | |
+1.57% | 23.46B | |
-11.99% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.87% | 17.19B | |
+6.03% | 13.99B | |
+36.16% | 12.53B |
- Stock Market
- Equities
- CTMX Stock